Indication
Metastatic castration-resistant prostate cancer
Metastatic castration-resistant prostate cancer is an advanced, incurable malignancy of the male reproductive system that has disseminated beyond the prostate gland to distant anatomical sites, most commonly the bones, distant lymph nodes, or visceral organs. Read more about Metastatic castration-resistant prostate cancer
62 drugs 52 manufacturers
Drugs that treat it
Common Metastatic castration-resistant prostate cancer therapies.
DOCETAXEL
DOCETAXEL
DOCETAXEL
DOCETAXEL
DOCETAXEL
DOCETAXEL
ABIRATERONE ACETATE
ABIRATERONE ACETATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMetastatic castration-resistant prostate cancer is an advanced, incurable malignancy of the male reproductive system that has disseminated beyond the prostate gland to distant anatomical sites, most commonly the bones, distant lymph nodes, or visceral organs.
It is defined clinically and biochemically by progressive disease—evidenced by rising serum prostate-specific antigen levels, objective radiologic progression, or worsening clinical symptoms—despite therapeutic or surgical androgen deprivation that maintains serum testosterone at castrate levels.
Pathophysiologically, the tumor develops resistance to standard testosterone-suppressing therapies through adaptive mechanisms such as androgen receptor gene alterations, splice variants, and intracrine steroid synthesis, allowing persistent oncogenic signaling.
- mayoclinic.org
Metastatic castration-resistant prostate cancer is an advanced, incurable malignancy of the male reproductive system that has disseminated beyond the prostate gland to distant anatomical sites, most commonly the bones, distant lymph nodes, or visceral organs
- nih.gov
Metastatic castration-resistant prostate cancer is an advanced, incurable malignancy of the male reproductive system that has disseminated beyond the prostate gland to distant anatomical sites, most commonly the bones, distant lymph nodes, or visceral organs It is defined clinically and biochemically by progressive disease—evidenced by rising serum prostate-specific antigen levels, objective radiologic progression, or worsening clinical symptoms—despite therapeutic or surgical androgen deprivati...
- inhibitortx.com
Metastatic castration-resistant prostate cancer is an advanced, incurable malignancy of the male reproductive system that has disseminated beyond the prostate gland to distant anatomical sites, most commonly the bones, distant lymph nodes, or visceral organs
- nih.gov
It is defined clinically and biochemically by progressive disease—evidenced by rising serum prostate-specific antigen levels, objective radiologic progression, or worsening clinical symptoms—despite therapeutic or surgical androgen deprivation that maintains serum testosterone at castrate levels
- nih.gov
It is defined clinically and biochemically by progressive disease—evidenced by rising serum prostate-specific antigen levels, objective radiologic progression, or worsening clinical symptoms—despite therapeutic or surgical androgen deprivation that maintains serum testosterone at castrate levels
- nih.gov
Pathophysiologically, the tumor develops resistance to standard testosterone-suppressing therapies through adaptive mechanisms such as androgen receptor gene alterations, splice variants, and intracrine steroid synthesis, allowing persistent oncogenic signaling
Personalize your experience
Follow Metastatic castration-resistant prostate cancer and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.